1
Think

Alpha-1-antitrypsin (A1AT) deficiency (also known as alpha-1) is the major known genetic risk factor for COPD1

 
90%
undiagnosed
More than 90% of those with alpha-1 are thought to be undiagnosed2
 
 
 
 
Up to 3% of patients diagnosed with COPD may have alpha-11,2
3 %
 
 
 
 
 
 
A1AT decrease
Alpha-1 is a genetic disease defined by decreased serum levels of A1AT3
 
 
 
 
 
 

Learn more

 
 
 
2
Test

Because alpha-1 is the major known genetic risk factor for COPD, all COPD patients should be tested regardless of smoking history1,3

 
 
 
 
 
 
Test
now
Early testing
for alpha-1 is key4
 
 
 
 
Simple, quick,
and accurate
Testing methods for alpha-1 are simple, quick, and accurate4
 
 
 
 
 
 
 
 
 
The only way
Laboratory testing is the only way to confirm a diagnosis of alpha-1 or to rule it out4
 
 
 
 
 

Learn more

 
 
3
Treat

The management of alpha-1 includes both nonpharmacologic and pharmacologic components3,5

 
 
Avoid
risk
factors
Avoidance of risk factors
is the first step3
 
 
 
 
Smoking
cessation
Smoking cessation is the most important preventive measure in the development of lung disease3,6
 
 
 
 
 
 
 
 
 
Treatment available
While there is no cure for alpha-1,
there are treatments available 3
 
 
 
 
 

Learn more

1
Think

Alpha-1-antitrypsin (A1AT) deficiency (also known as alpha-1) is the major known genetic risk factor for COPD1

 
90%
undiagnosed
More than 90% of those with alpha-1 are thought to be undiagnosed2
 
 
 
 
Up to 3% of patients diagnosed with COPD may have alpha-11,2
3 %
 
 
 
 
 
 
A1AT decrease
Alpha-1 is a genetic disease defined by decreased serum levels of A1AT3
 
 
 
 
 
 

Learn more

 
 
 
2
Test

Because alpha-1 is the major known genetic risk factor for COPD, all COPD patients should be tested regardless of smoking history1,3

 
 
 
 
 
 
Test
now
Early testing
for alpha-1 is key4
 
 
 
Simple, quick,
and accurate
Testing methods for alpha-1 are simple, quick, and accurate4
 
 
 
 
 
 
 
 
The only way
Laboratory testing is the only way to confirm a diagnosis of alpha-1 or to rule it out4
 
 
 
 
 

Learn more

 
 
3
Treat

The management of alpha-1 includes both nonpharmacologic and pharmacologic components3,5

 
 
Avoid
risk
factors
Avoidance of risk factors
is the first step3
 
 
 
 
Smoking
cessation
Smoking cessation is the most important preventive measure in the development
of lung disease3,6
 
 
 
 
 
 
 
 
 
Treatment available
While there is no cure for alpha-1, there are treatments available 3
 
 
 
 
 

Learn more

1
Think

Alpha-1-antitrypsin (A1AT) deficiency (also known as alpha-1) is the major known genetic risk factor for COPD1

 
90%
undiagnosed
More than 90% of thosewith alpha-1
are thought to be undiagnosed2
 
 
 
3 %
Up to 3% of patients diagnosed
with COPD may have alpha-11,2
 
 
 
 
 
 
A1AT decrease
Alpha-1 is a genetic disease defined by decreased serum 
levels of A1AT3
 
 
 
 
 
 

Learn more

 
 
2
Test

Because alpha-1 is the major known genetic risk factor for COPD, all COPD patients should be tested regardless of smoking history1,3

 
Test now
Early testing
for alpha-1 is key4
 
 
 
The only way
Laboratory testing is the only way to confirm a diagnosis of alpha-1
or to rule it out4
 
 
 
 
 
 
Simple, quick, and accurate
Testing methods for alpha-1 are simple, quick, and accurate3
 
 
 
 
 
 

Learn more

 
 
3
Treat

The management of alpha-1 includes both nonpharmacologic and pharmacologic components3,5

 
Avoid
risk
factors
Avoidance of risk factors
is the first step3
 
 
 
Smoking
cessation
Smoking cessation
is the most important preventive measure in the development of lung disease3,6
 
 
 
 
 
 
Treatment available
While there is no cure for alpha-1, there are treatments available 3
 
 
 
 
 
 

Learn more

 

References

  1. World Health Organization. α 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75(5):397-415.
  2. Campos MA, Wanner A, Zhang G, et al. Trends in the diagnosis of symptomatic patients with α1-antitrypin deficiency between 1968 and 2003. Chest. 2005; 128(3):1179-1186.
  3. American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818-900.
  4. Alpha-1 Foundation. What is Alpha-1? http://alpha-1foundation.org/what-is-alpha-1/. Accessed July 14, 2016.
  5. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2016. http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/. Accessed July 14, 2016.
  6. Bals R, Kohnlein T. Alpha-1 antitrypsin deficiency. Stuttgart: George Thieme Verlag KG; 2009.

This site is intended only for healthcare professionals. The information herein provided is educational and should not be treated or viewed as promotional material